Moexa Pharmaceuticals, Inc.

Moexa’s is a pre-clinical biotech advancing new anti-cancer and anti-fibrosis small molecule SMAD signaling therapeutics to clinic. We combine AI modeling to support traditional FDA IND requirements. Our strategy streamlines and expedites drug discovery for IND clearance and first-in-human clinical trials. We have agreed to Phase 1 trial plans with a top 5 CRO partner, and we are actively seeking to expand other partnerships and collaborations. We welcome your inquiry on how we can cooperate with you if you are interested in ground floor participation on a promising new drug discovery that could impact the sector. Our innovations include invention of novel small molecule NCEs prepared for first time therapeutic use in humans on cancer, immuno-oncology, and fibrosis. Our unique AI SMAD heterotrimer is deployed for in-silico 3D RNA sequencing, precluding standardised in-vivo studies to refine and expedite traditional lead optimisation for design of our new drugs. Our tumor eradicating products are being tested to work as standalone therapeutics or in co-active use with other FDA approved drugs already in market. Our IP library of over 75 global patents confirms the novelty and value of our technology. Our small molecule SMAD3 inhibition IP leads all Pharma worldwide. We have recently been awarded markush claim rights in the US, with our molecules qualified for broad use. Our IP presently cover all major markets with active expansion into secondary markets. This IP footprint captures more than 7 billion people, and 10 specified cancers and fibrosis with a collective annual therapeutic market value of US$200 billion worldwide for related products. We are pleased to meet parties interested in further discussions.